26 th Congress of EAHP
23st – 25rd March 2022

4CPS-241

Effectiveness, Durability, and Safety of Dolutegravir and Lamivudine Versus Tenofovir alafenamide, Emtricitabine and Bictegravir in a Real-Life Cohort of HIV-Infected Adults.

Mendoza Acosta I[1], Lázaro López A[1], Martínez Ruiz E[1], Tardáguila Molina P[1], Casarrubios Lázaro GI[1], Horta Hernandez AM[1], M. Torralba González De Suso[2].1Guadalajara University Hospital, Pharmacy Department, Guadalajara, Spain. 2Guadalajara University Hospital, Research Department, Guadalajara, Spain.

Background and Importance

Dolutegravir plus lamivudine: initial and switch option in HIV-1 treatment.
¿**real-world studies** on the **effectiveness, durability and, safety** of two-drug regimens (2-DR) compared to three-drug regimens (3-DR)?

Aim and Objectives

VIROLOGICAL EFFECTIVENESS + DURABILITY + SAFETY

Intention-to-treat-exposed analysis **at 24 weeks in a real-life** cohort of HIV-1 treatment-naïve (TN) and treatment-experienced (TE) patients.

2-DR (DTG+3TC)
Vs
3-DR (TAF/FTC/BIC)

Materials and Methods

Observational and ambispective study

All TN and TE patients with 2-DR or 3-DR

July 01, 2018, and September 30, 2021

Primary endpoint
% TN patients with VL<50
% TE patients with VL≥50

Secondary endpoints
% of patients that continued with treatment
Number of adverse events (AE)

Statistical analyses were performed with Stata 15.0.

Results

TN (n=27)

2-DR (74%)
LogVL= 4.6 (4.1-5.1)

3-DR (26%)
LogVL= 5.4 (3.9-6)

TE (n=212)

2-DR (55%)
84.6 %VL<50 copies/mL

3-DR (45%)
73.7% VL<50 copies/mL

VIROLOGICAL EFECTIVENESS



Group	% VL≥50 copies/mL	
2-DR	20%	p=0.71
3-DR	29%	



Group	% VL<50 copies/mL	
2-DR	85.5%	p=0.74
3-DR	87.5%	

DURABILITY

(% patients continued with treatment at week 24)

TN: 95% 2-DR Vs 93.8% of 3-DR

TE: 93.8% 2-DR Vs 91.2% of 3-DR

SAFETY

% (n) of patients that reported any AE

TN			TE		
2-DR	**3-DR**	p	**2-DR**	**3-DR**	**p**
40% (8)	28.6% (2)	0.68	19.7% (23)	26.3%(25)	0.25

Conclusion and Relevance

Our results show a **similar effectiveness profile** of DTG plus 3TC compared with TAF/FTC/BIC at 24 weeks. Additionally**, durability and safety of 2-DR were confirmed to be similar to 3-DR**.

@inesmendoza91
@Farmacia_HUGU

imendoza.acosta91@gmail.com